Humacyte (HUMA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.1M

Revenue (quarter)

$406,000.00

Revenue growth (year over year)

+34.88%

Gross profit (trailing twelve months)

−$10.5M

Gross margin

−494.58%

Net income (trailing twelve months)

−$96.7M

Net income (quarter)

−$36.8M

Net income growth (year over year)

+2.27%

Net margin

−4560.82%

Return on equity

−547.87%

EPS (trailing twelve months)

−$0.52

Book value per share

$0.11

P/E (trailing twelve months)

—

Price to book

3.53

Debt to assets

77.36%

Payout ratio

—

Dividend yield

—

Company profile

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

• Is Humacyte (HUMA) profitable?

  No. Humacyte reported a net loss of $96.7M over the trailing twelve months.

• How much revenue does Humacyte (HUMA) make?

  Humacyte generated $2.1M in revenue over the trailing twelve months, up 34.88% year over year.

• How do I buy stock in Humacyte (HUMA)?

  HUMA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.